Avicanna (AVCN.TO) swung to a net comprehensive loss in the first quarter compared to a year-ago gain, it said on Thursday.
For the three months ended March 31, 2026, the company reported net comprehensive loss of $214,653 or breakeven per share, compared with net comprehensive gain of $876,331 or net comprehensive gain per share of $0.01, a year earlier.
Revenue for the first quarter increased to $6.7 million, compared with $6.3 million, a year-ago. Growth was primarily driven by an 11% increase in MyMedi.ca revenue and a 24% increase in product sales in Canada compared to the same period in 2025, it said.
Shares of the company closed down 3.9% to $0.125 on Wednesday on the Toronto Stock Exchange.